- ImmunoGen Touts Additional Positive Data From Ovarian Cancer Drug, Seeks Expanded Use Approval, Stock Soars Yahoo Finance
- ImmunoGen Touts Additional Positive Data From Ovarian Cancer Drug, Seeks Expanded Use Approval, Stock Soa Benzinga
- ImmunoGen’s Elahere delivers landmark ovarian cancer win FiercePharma
- ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer Yahoo Finance
- Why ImmunoGen Stock Is Blasting Off Wednesday – Immunogen (NASDAQ:IMGN) Benzinga
- View Full Coverage on Google News
Read original article here